1. Philip Morris leads the industry shift to smoke-free alternatives, deriving 42% of revenue from products like IQOS and Zyn; 2. Strong Q1 2025 results show 10.2% organic revenue growth, margin expansion, and upgraded earnings guidance; 3. Despite regulatory risks and a premium valuation, its stable cash flow and dividend growth justify a strong buy rating for income-focused investors.